| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 48.25 | 6.3% | 3.9% |
| Total Income | 48.25 | 6.3% | 3.9% |
| Expenditure | 59.79 | 0.9% | 9.3% |
| PBT | — | ||
| Net Profit | -12.57 | 20.8% | 22.8% |
| OPM | -23.90% | 9.07pp | 7.32pp |
| NPM | -26.04% | 8.94pp | 6.39pp |
| EPS | -0.19 | 20.8% | 26.9% |
Treace Medical Concepts Reports Q3 2026 Financial Results
06 Nov 2026 · 28m ago
Summary
Treace Medical Concepts reported third quarter 2026 revenue of $48.3 million, a 4% decrease year-over-year, attributed to a shift in revenue mix and lower bunion kit volumes. However, the company improved its net loss by 23% to $(12.6) million and saw Adjusted EBITDA increase to $0.3 million. Year-to-date cash usage was reduced by 53%. Management expressed encouragement regarding accelerated double-digit case volume growth and continued market share gains, emphasizing a balanced approach to investments and profitability.
Key Highlights
- 1
Revenue for the third quarter of 2026 was $48.3 million, a decrease of 4% compared to $50.2 million in the third quarter of 2025.
- 2
Net loss for the third quarter of 2026 improved by $3.7 million to $(12.6) million, or $(0.19) per share, compared to $(16.3) million, or $(0.26) per share, for the same period in 2025.
- 3
Adjusted EBITDA increased by $2.9 million to $0.3 million in the third quarter of 2026 compared to $(2.6) million for the same period in 2025.
- 4
Year-to-date cash usage was reduced by 53% or $9.7 million when compared to the same period in 2025.
- 5
Announced 5-Year results of a prospective, multicenter study demonstrating long term, positive outcomes of the Lapiplasty® procedure, a first-in-industry milestone.
- 6
Increased adoption of expanded bunion portfolio with approximately 45% of Lapiplasty® surgeon users now incorporating one or more of the Company’s three new bunion systems launched in the third quarter 2025.
Management Comments
John T. Treace
We are encouraged by our third quarter performance, reflecting accelerated double-digit case volume growth and continued market share gains – driven by increasing adoption of our comprehensive range of best-in-class bunion systems, as well as our expanding portfolio of new technologies including our SuperBite™ compression screws. These new product offerings are allowing us to penetrate a much broader range of our surgeon customers’ most common foot and ankle procedures. We continue to make disciplined investments in key growth initiatives with an emphasis on our product pipeline, while staying focused on improving profitability and reducing cash usage. We believe this balanced approach positions us to build momentum and deliver stronger growth to finish the year.
Informational and educational content only. Not investment advice.